Zu "K07370" wurden 133 Artikel gefunden!
Für die Filterung wurden keine Ergebnisse gefunden!
BTK IN-1
Artikelnummer: TGM-TQ0230-100mg
Description: BTK IN-1 [SNS062 analog] is an effective BTK inhibitor with an IC50 of less than 100 nM. Target: BTK. Smiles: Clc1cccc(NCC(=O)NC2CCCN(C2)c2ncnc3[nH]ccc23)c1. References: Minna Bui, et al. Heteroaryl btk inhibitors. WO2011029043A1
| Schlagworte: | SNS062 analog |
| Anwendung: | BTK (Bruton's tyrosine kinase ) inhibitor |
| CAS | 1270014-40-8 |
| MW: | 384.86 D |
ab 35,00 €
Tirabrutinib
Artikelnummer: TGM-TQ0236-100mg
Description: Tirabrutinib (GS-4059) (ONO-4059) is an orally active Bruton's Tyrosine Kinase (Btk) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib irreversibly and covalently binds to Btk and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of...
| Schlagworte: | ONO-4059, Velexbru, GS-4059 |
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 1351636-18-4 |
| MW: | 454.48 D |
ab 41,00 €
Fenebrutinib
Artikelnummer: TGM-TQ0242-10mg
Description: Fenebrutinib (GDC-0853) is a selective and noncovalent inhibitor of Bruton's tyrosine kinase (Btk) with a Ki of 0.91 nM. Target: BTK. Smiles: C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1. References: Erickson RI , et al. Bruton's Tyrosine Kinase Small Molecule...
| Schlagworte: | GDC-0853 |
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 1434048-34-6 |
| MW: | 664.8 D |
ab 38,00 €
RN486
Artikelnummer: TGM-T1976-100mg
Description: RN486 is an effective and specific BTK inhibitor (IC50: 4 nM). Target: BTK. Smiles: CN1CCN(CC1)c1ccc(Nc2cc(cn(C)c2=O)-c2cccc(c2CO)-n2ccc3cc(cc(F)c3c2=O)C2CC2)nc1. References: Xu D, et al. J Pharmacol Exp Ther, 2012, 341(1), 90-103.
| Anwendung: | BTK inhibitor |
| CAS | 1242156-23-5 |
| MW: | 606.69 D |
ab 78,00 €
BTK inhibitor 10
Artikelnummer: TGM-T10627-100mg
Description: BTK inhibitor 10 is a potent and orally active compound with potential applications in rheumatoid arthritis treatment. Target: Others. Smiles: C=CC(=O)Nc1cccc(Oc2ncnc3[nH]c(cc23)-c2ccc(cc2)N2CCOCC2)c1. References: HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor,...
| Anwendung: | BTK inhibitor |
| CAS | 2241732-30-7 |
| MW: | 441.48 D |
ab 1.521,00 €
BTK inhibitor 13
Artikelnummer: TGM-T10628-100mg
Description: BTK inhibitor 13 (compound 8) is a potent and selective BTK inhibitor with an IC50 of 1.2 nM. Target: Others. Smiles: C(CN(C(C=C)=O)C)(=O)C=1C2=C(N=CN=C2NC1)C3=C(C)C(NC(=O)C4=CC=C(C=C4)C5CC5)=CC(F)=C3. References: Pulz R, et al. Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine...
| Anwendung: | BTK inhibitor |
| CAS | 2376726-26-8 |
| MW: | 511.55 D |
ab 1.972,00 €
Btk inhibitor 2
Artikelnummer: TGM-T10629-100mg
Description: Btk Inhibitor 2 (BGB-3111 analog) is a BTK inhibitor. Target: BTK. Smiles: NC(=O)c1c(N)n(nc1-c1ccc(Oc2ccccc2)cc1)[C@@H]1CCCN(C1)C(=O)C=C. References: Cecile M. Krejsa. Methods of Using BTK Inhibitors to Treat Dermatoses. US 20170224688 A1.
| Schlagworte: | BGB-3111 analog |
| Anwendung: | Btk inhibitor |
| CAS | 1558036-85-3 |
| MW: | 431.49 D |
ab 34,00 €
MT-802
Artikelnummer: TGM-T16157-100mg
Description: MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL). Target: PROTACs, BTK. Smiles: NC1=C2C(=NN(C2=NC=N1)C3CCN(CCOCCOCC(NC=4C=C5C(=CC4)C(=O)N(C5=O)C6C(=O)NC(=O)CC6)=O)CC3)C7=CC=C(OC8=CC=CC=C8)C=C7....
| Anwendung: | BTK degradation driving PROTAC |
| CAS | 2231744-29-7 |
| MW: | 787.82 D |
ab 147,00 €
ARQ 531
Artikelnummer: TGM-T14323-100mg
Description: ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively. Target: BTK. Smiles: OC[C@@H]1CC[C@H](CO1)Nc1ncnc2[nH]cc(C(=O)c3ccc(Oc4ccccc4)cc3Cl)c12. References: S Eathiraj, et al. Targeting...
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 2095393-15-8 |
| MW: | 478.93 D |
ab 53,00 €
Spebrutinib besylate
Artikelnummer: TGM-T14357-100mg
Description: Spebrutinib besylate (AVL-292 benzenesulfonate, CC-292 besylate) is a Btk kinase activity inhibitor with an IC50 of less than 0.5 nM and a Kinact/Ki of 7.69×10^4 M^-1s^-1. Target: BTK. Smiles: O=C(C=C)NC1=CC=CC(=C1)NC2=NC(=NC=C2F)NC3=CC=C(OCCOC)C=C3.O=S(=O)(O)C=1C=CC=CC1. References: Evans EK, et al....
| Schlagworte: | AVL-292 (benzenesulfonate), CC-292 (besylate) |
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 1360053-81-1 |
| MW: | 581.62 D |
ab 1.521,00 €
Remibrutinib
Artikelnummer: TGM-T16730-100mg
Description: Remibrutinib inhibits BTK activity with an IC50 value of 0.023 µM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment. Target: BTK. Smiles:...
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 1787294-07-8 |
| MW: | 507.53 D |
ab 98,00 €
Acalabrutinib
Artikelnummer: TGM-T3626-100mg
Description: Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This...
| Schlagworte: | ACP-196 |
| Anwendung: | Targets Bruton agammaglobulinemia tyrosine kinase [EC:2.7.10.2] (BTK) |
| CAS | 1420477-60-6 |
| MW: | 465.51 D |
ab 41,00 €